Immuno-Oncology | Specialty

FDA Expands Pemetrexed Approval for Frontline Pembrolizumab/Chemo Combo in NSCLC

January 31st 2019

The FDA has expanded the indication for pemetrexed in combination with pembrolizumab and platinum-based chemotherapy for the first-line treatment of patients with metastatic nonsquamous non–small cell lung cancer without EGFR or ALK alterations.

Dr. Socinski on Immunotherapy Approaches in Squamous NSCLC

January 30th 2019

Mark A. Socinski, MD, executive medical director, AdventHealth Medical Group, discusses combination versus single-agent immunotherapy in patients with squamous non–small cell lung cancer.

Brahmer Provides a Glimpse of Future Immunotherapeutics in NSCLC

January 28th 2019

Despite the rapidly expanding therapeutic options available in immunotherapy for patients with non-small cell lung cancer, there are still a number of drawbacks to treatment, explaining why not all patients respond to current treatment options.

Lilenbaum Examines EGFR+ NSCLC Advancements and Potential Role of Immunotherapy

January 27th 2019

Rogerio Lilenbaum, MD, highlights the current treatment approaches for patients with EGFR-positive non–small cell lung cancer and shed light on the potential for immunotherapy in the space.

Dr. Brahmer on Managing Immune-Related AEs in Lung Cancer

January 26th 2019

Julie R. Brahmer, MD, associate professor of oncology, co-director of the Upper Aerodigestive Department, Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses managing immune-related adverse events in lung cancer.

Dr. Garon on Potential for Immunotherapy in EGFR+ NSCLC

January 26th 2019

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses the potential for immunotherapy in the treatment of patients with EGFR-positive non–small cell lung cancer.

BMS Withdraws Application for Nivolumab/Ipilimumab in TMB-High NSCLC

January 24th 2019

Bristol-Myers Squibb has withdrawn its supplemental biologics license application for the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the frontline treatment of patients with advanced non–small cell lung cancer with tumor mutational burden ≥10 mutations per megabase.

Evidence Grows for Earlier Immunotherapy in NSCLC

January 24th 2019

Clinical trial evidence is building for moving checkpoint blockade immunotherapy forward in the treatment timeline for non–small cell lung cancer, but improving patient selection for these therapies remains a key challenge.

Dr. Choueiri Discusses Immunotherapy in RCC

January 23rd 2019

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses immunotherapy in the treatment of patients with renal cell carcinoma.

Dr. Sabari Discusses Role of Immunotherapy in SCLC

January 18th 2019

Joshua K. Sabari, MD, assistant professor of medicine, NYU Langone's Perlmutter Cancer Center, discusses the role of immunotherapy in the treatment of patients with small cell lung cancer.

Immunotherapy/Chemo Combinations Show Continued Benefit in NSCLC

January 17th 2019

Several clinical trials have evaluated the addition of immunotherapy to standard chemotherapy in the frontline treatment of patients with advanced non–small cell lung cancer, all of which echo similar conclusions: these combinations are a mainstay in this population.

Controversy Adds Caution to CRISPR Editing in United States

January 17th 2019

The development of cancer treatments and diagnostic tools using CRISPR/Cas9 and other gene-editing technology is a promising area of research in the United States, although the field is moving into human studies at a relatively slow pace.

FDA Accepts sBLA for Frontline Atezolizumab Plus Carboplatin/Nab-Paclitaxel in Nonsquamous NSCLC

January 17th 2019

The FDA has accepted a supplemental biologics license application for atezolizumab, carboplatin, and nab-paclitaxel as a first-line treatment for patients with metastatic nonsquamous non–small cell lung cancer.

Dr. Subramanian on Ongoing Trials for Patients With Nonsquamous NSCLC

January 16th 2019

Janakiraman Subramanian, MD, medical oncologist, director of Thoracic Oncology, Center for Precision Medicine, Saint Luke’s Cancer Institute, discusses ongoing trials evaluating the use of immunotherapy in patients with nonsquamous non–small cell lung cancer (NSCLC).

Grivas Discusses Developments in Bladder Cancer

January 16th 2019

Petros Grivas, MD, PhD, discusses the rapidly evolving field of locally advanced and metastatic bladder cancer.

Dr. Wright Discusses Immunotherapy in Bladder Cancer

January 15th 2019

Jonathan L. Wright, MD, MS, FACS, medical director, Urology Clinic, University of Washington Medical Center, affiliate investigator, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, discusses immunotherapy in bladder cancer.

Nivolumab/Ipilimumab Combo Approved in Europe for Frontline RCC

January 15th 2019

The European Commission has approved nivolumab combined with low-dose ipilimumab as a frontline treatment for patients with intermediate- and poor-risk advanced renal cell carcinoma.

Immunotherapy/VEGF Inhibitor Combos to Define Frontline Standard in mRCC

January 14th 2019

Sumanta K. Pal, highlights the different combination regimens that are making headlines in the treatment of patients with metastatic renal cell carcinoma.

Dr. Figlin on Considerations for Combining TKIs and Immunotherapy in RCC

January 10th 2019

Robert A. Figlin, MD, director, Division of Hematology/Oncology, Steven Spielberg Professor of Biomedical Sciences and Medicine, Cedars-Sinai Medical Center, discusses considerations when combining TKIs and immunotherapy agents in the management of advanced renal cell carcinoma.

Checkpoint Inhibitors Herald New Era in Urothelial Cancer

January 9th 2019

Immune checkpoint inhibitors, with their favorable safety and antitumor activity profiles, have heralded a new era in urothelial carcinoma treatment.